NCT06180889View on ClinicalTrials.gov

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

241

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 15, 2025

Study Completion Date

April 15, 2026

Conditions
Knee Arthroplasty, Total
Interventions
DRUG

Enoxaparin

40 mg enoxaparin administered as subcutaneous injection once daily

DRUG

KN060 Low

Single dose of KN060 administered as intravenous infusion

DRUG

KN060 Middle

Single dose of KN060 administered as intravenous infusion

DRUG

KN060 Hight

Single dose of KN060 administered as intravenous infusion

Trial Locations (1)

Unknown

Shanghai Sixth People's Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Alphamab Co., Ltd.

INDUSTRY

NCT06180889 - Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter